🗞 Forbion, a European life sciences venture capital firm, is participating in oversubscribed Series B financing rounds in two US-based companies: Capstan Therapeutics Inc. and Engrail Therapeutics. Both rounds have exceeded their targets and Forbion joined as a new investor. Engrail Therapeutics raised $157 million and focuses on developing therapies for neurological disorders. Capstan Therapeutics raised $175 million and is focused on in vivo cell therapy.
📢 Forbion Joins Oversubscribed US Financing Rounds
Introduction:
European life sciences venture capital firm Forbion has announced its participation in oversubscribed Series B financing rounds for Capstan Therapeutics Inc. and Engrail Therapeutics, both located in San Diego, USA.
Main points:
- Engrail Therapeutics closed a $157 million Series B financing round, co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners. The company focuses on the development of therapies for anxiety disorders, depression, PTSD, and rare neurodegenerative diseases.
- Capstan Therapeutics closed a $175 million Series B financing round, led by RA Capital Management and with participation from new investors Johnson & Johnson Innovation, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments. The company focuses on in vivo cell reprogramming through RNA delivery.
- Forbion’s investments in both companies mark its tenth investment from its Growth Opportunities II Fund, which raised €600 million in 2023.
Conclusion:
Forbion’s participation in these financing rounds demonstrates its continued investment in innovative life sciences companies in the US. Both Engrail Therapeutics and Capstan Therapeutics are developing promising treatments for neurological disorders, indicating a growing focus on this therapeutic area in the biotech industry.
